AR121515A1 - Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores - Google Patents

Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Info

Publication number
AR121515A1
AR121515A1 ARP210100576A ARP210100576A AR121515A1 AR 121515 A1 AR121515 A1 AR 121515A1 AR P210100576 A ARP210100576 A AR P210100576A AR P210100576 A ARP210100576 A AR P210100576A AR 121515 A1 AR121515 A1 AR 121515A1
Authority
AR
Argentina
Prior art keywords
efficacy
methods
evaluate
compositions
transporter inhibitors
Prior art date
Application number
ARP210100576A
Other languages
English (en)
Spanish (es)
Inventor
Hong Sun
Xiaojun Li
Zafrin Dhali
Haiping Lu
Wilson Wu
Wen Luo
John W Whitaker
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of AR121515A1 publication Critical patent/AR121515A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP210100576A 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores AR121515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06

Publications (1)

Publication Number Publication Date
AR121515A1 true AR121515A1 (es) 2022-06-08

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100576A AR121515A1 (es) 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Country Status (13)

Country Link
US (1) US12612661B2 (https=)
EP (1) EP4106872A4 (https=)
JP (1) JP2023515665A (https=)
KR (1) KR20230005816A (https=)
CN (1) CN115515680A (https=)
AR (1) AR121515A1 (https=)
AU (1) AU2021231683A1 (https=)
BR (1) BR112022017770A2 (https=)
CA (1) CA3174572A1 (https=)
IL (1) IL296168A (https=)
MX (1) MX2022010816A (https=)
TW (1) TW202146660A (https=)
WO (1) WO2021178166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6945457B1 (en) * 1996-05-10 2005-09-20 Transaction Holdings Ltd. L.L.C. Automated transaction machine
JP4198582B2 (ja) * 2003-12-02 2008-12-17 独立行政法人科学技術振興機構 タンタルオキシナイトライド酸素還元電極触媒
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2243834A1 (en) 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
EP2707498B1 (en) 2011-01-31 2018-01-17 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2838207A1 (en) 2011-06-08 2012-12-13 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid x receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
TR201907106T4 (tr) 2014-03-14 2019-06-21 Caredx Inc Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.

Also Published As

Publication number Publication date
US12612661B2 (en) 2026-04-28
CN115515680A (zh) 2022-12-23
WO2021178166A1 (en) 2021-09-10
CA3174572A1 (en) 2021-09-10
US20230193388A1 (en) 2023-06-22
MX2022010816A (es) 2022-12-13
BR112022017770A2 (pt) 2022-11-29
JP2023515665A (ja) 2023-04-13
TW202146660A (zh) 2021-12-16
EP4106872A4 (en) 2024-04-10
EP4106872A1 (en) 2022-12-28
KR20230005816A (ko) 2023-01-10
IL296168A (en) 2022-11-01
AU2021231683A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
AR119676A1 (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
CL2019000973A1 (es) Método y sistemas para la indexación de datos bioinformáticos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CO2022013827A2 (es) Compuestos y métodos para modular el empalme
AR117918A1 (es) COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CO2019004630A2 (es) Composiciones de células t con car anti-bcma
MX2020002542A (es) Variantes de interleucina-18 y metodos de uso.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2020012561A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
CO2022015925A2 (es) Compuestos y métodos para modular el corte y empalme
AR121515A1 (es) Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CL2022002779A1 (es) Compuestos y métodos para modular el proceso de corte y empalme
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
CR20120303A (es) Tratamientos para trastornos gastrointestinales
BR112018002503A2 (pt) comutador em cascata entre pluralidades de lnas
MX2018003301A (es) Inhibidores de pcna.
CO2023015915A2 (es) Anticuerpos anti-ccr8
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
MX383670B (es) Nuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos.
CO2022000705A2 (es) Receptor de antígeno quimérico (car) anti-hk2
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.